ALZAI health for Cognitive Longevity

AI-Powered Early Alzheimer's Risk Detection for Longevity, Personalized Medicine & Digital Health

THE PROBLEM

Preventive brain health is a major unmet need in the longevity and digital health markets.

- Alzheimer's Disease (AD) risk develops silently years before symptoms
- Only 20% of cases are diagnosed by doctors
- Even high-performing, health-conscious individuals lack visibility into AD risk

Existing diagnostic tools are:

- → Expensive
- → Invasive
- → Not scalable for routine screening
- → Not deployed early enough

The result: *Brain health is still reactive, not proactive—even in the most advanced healthcare settings.*

THE ALZAI SOLUTION

ALZAI enables proactive cognitive risk assessment at scale

Using routine health data, ALZAI:

- Identifies individuals at high risk of Alzheimer's up to 10 years in advance
- Stratifies users by projected time-to-risk
- Flags patients in the **early stages**
- Enables **personalized prevention & yearly monitoring**

Key advantages:

- No new tests required
- Non-invasive
- Affordable & fast
- Seamless workflow integration
- Scalable across populations

Step 01

Routine Labs / Platform Onboarding

1 week

Step 02

AI Risk Identification

1 day

Step 03

Personalized risk insights delivered

1 day

Step 04

Ongoing monitoring (annually)

1x a year

Results

Rapid early identification years before symptoms appear

Increased engagement, retention & premium upgrades

THE VALUE

- Enhance user insight
  - Deliver one of the most meaningful long-term health signals
- Differentiate your services
  - Offer cutting-edge AI-driven cognitive risk screening not available in standard health panels
- Unlock prevention pathways
  - Lifestyle interventions can reduce dementia risk by ~40%

Increased engagement & retention:

- High-impact, personalized outputs drive repeat usage and platform stickiness
- **Supports upsell of offerings:**
  - advanced diagnostics
  - coaching programs
  - supplements / interventions
  - subscriptions services

CLINICAL VALIDATION

Retrospective Multinational Study

- **1.6M+** patient records analyzed
- Data sources: **over 100M** datasets from Clalit Health Services (Israel) and HealthVerity (USA)
- Population: **Diverse populations from across the USA** and Israel
- Outcome: Validation of ALZAI's ability to identify high-risk individuals in the years immediately preceding clinical onset, enabling earlier detection within the preventive care window

ALZAI demonstrated robust predictive performance in identifying individuals at elevated risk of Alzheimer's disease in early stages – which supports earlier detection, enables proactive cognitive health management, and improves long-term health outcomes.

LEADERSHIP TEAM



Hayim Raclaw
Chairperson, Chief Executive Officer & Co-founder



Dr. Amir Glik, MD
Director, Chief Medical Officer & Co-founder



Roy Kait
Director, Chief Revenue Officer & Co-founder



Prof. Chen Hajaj
Head of Data Science & Co-founder

PARTNERS

CLALIT HEALTH

ARIEL UNIVERSITY

healthverity®

ABOUT US

ALZAI Health Corp. is a predictive AI healthcare company focused on enabling early detection of under-diagnosed chronic diseases through non-invasive, data-driven risk stratification. Our platform identifies individuals at elevated risk **before symptoms appear**, enabling proactive intervention at scale.

Key capabilities:

- Leverages existing healthcare data (EHR + labs)
- Identifies patients years before diagnosis
- Enables proactive clinical intervention at scale

CONTACT US

info@alzaihealth.com

+1.416.727.6244

https://www.alzaihealth.com